Merck & Co., Inc. (NYSE:MRK – Get Free Report) EVP Richard Deluca sold 6,050 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $130.38, for a total value of $788,799.00. Following the completion of the sale, the executive vice president owned 155,487 shares in the company, valued at $20,272,395.06. This represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Merck & Co., Inc. Trading Up 1.7%
Shares of NYSE MRK traded up $2.14 during mid-day trading on Monday, reaching $130.72. 5,200,151 shares of the company’s stock were exchanged, compared to its average volume of 10,735,965. The firm has a market capitalization of $322.85 billion, a price-to-earnings ratio of 104.58, a PEG ratio of 5.56 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.05. The company’s 50-day moving average is $123.98 and its 200-day moving average is $119.18.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
Wall Street Analysts Forecast Growth
MRK has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Scotiabank boosted their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Guggenheim upped their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $134.56.
Read Our Latest Stock Analysis on MRK
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of MRK. Brighton Jones LLC increased its position in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC grew its stake in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after buying an additional 359,356 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
About Merck & Co., Inc.
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.jpg){kind=logo}
